Spero Therapeutics, Inc.
SPRO · NASDAQ
Market closed$1.58$0.010000 (+0.64%)After hours $1.57 · -0.63%
Key statistics
Previous close$1.57
Open$1.54
Day high$1.64
Day low$1.50
52-week high$3.08
52-week low$1.50
Market cap91.48M
Volume1.25M
Average volume1.23M
P/E ratio6.58
Forward P/E—
EPS0.24
Dividend yield0.00%
Market context
Why it moved
SPRO (Spero Therapeutics) edged modestly higher in light trading, with the slight gain appearing to reflect general positive market sentiment rather than any specific company news or catalyst identified today.
What is happening
Recent company-specific developments and publisher coverage.
Reuters · July 14, 2026Spero licenses Innovent's experimental immune disease drug for up to $1.1 billionThe Business Journals · July 14, 2026Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunologyQuiver Quantitative · July 14, 2026Spero Therapeutics Secures $105 Million Royalty Financing to Advance SP001 and Extend Cash Runway Through Second Half of 2029AllSci · July 14, 2026Spero Therapeutics Secures $105M Non-Dilutive FinancingStock Titan · June 25, 2026Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock planSeeking Alpha · June 18, 2026Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering (NASDAQ:SPRO)Investing.com · June 18, 2026Spero Therapeutics stock surges on FDA approval of UtebziGlobeNewswire · May 13, 2026Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update Mt Newswire · July 14, 2026Spero Therapeutics Licenses Immunology Drug Candidate From Innovent, Recieves $105 Million Financing Benzinga · July 14, 2026Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty Benzinga · July 14, 2026Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China Benzinga · June 17, 2026GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs Mt Newswire · June 17, 2026GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections Benzinga · June 17, 2026GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections Benzinga · May 13, 2026Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY Mt Newswire · March 26, 2026Spero Therapeutics Q4 Swings to Profit, Revenue Rises